In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes - the ruthenium(II/III)-dithiocarbamates - which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines.

Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?

NARDON, CHIARA;
2016-01-01

Abstract

In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes - the ruthenium(II/III)-dithiocarbamates - which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines.
cancer
chemoprotectant
cisplatin
dithiocarbamate
heteroleptic
homoleptic
metal complexes
NAMI-A
redox reaction
ruthenium
File in questo prodotto:
File Dimensione Formato  
Future Medicinal Chemistry Volume issue 2016 doi 10.4155_fmc.15.175 Nardon Chiara; Brustolin Leonardo; Fregona Dolores -- Is matching ruthenium wit.pdf

non disponibili

Dimensione 865.94 kB
Formato Adobe PDF
865.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Supplementary.pdf

non disponibili

Dimensione 178.02 kB
Formato Adobe PDF
178.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1062926
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
social impact